Routine Systematic Prostate Biopsies not Replaced by Magnetic Resonance Imaging-Targeted Biopsy

Gómez-Ortiz, David; Garza-Gangemi, Adrián M.; Oropeza-Aguilar, Mariano; Rangel-Suárez, Sergio; Espinosa-Cruz, Verónica; Villegas-Hernández, Antonio C.; Martínez-Martínez, Ricardo; Castillejos-Molina, Ricardo A..
Rev. invest. clín ; 74(4): 212-218, Jul.-Aug. 2022. tab, graf
Artículo en Inglés | LILACS-Express | ID: biblio-1409583

Documentos relacionados

  1. Routine systematic prostate biopsies not replaced by magnetic resonance imaging-targeted biopsy.
  2. Is multiparametric MRI always needed in biopsy-naïve patients with abnormal digital rectal examination? A single-institutional experience combining clinical and micro-ultrasonography-based factors to optimize prostate cancer detection.
  3. Ultrasound fusion biopsy.
  4. Optimizing multiparametric magnetic resonance imaging-targeted biopsy and detection of clinically significant prostate cancer: the role of core number and location.
  5. Using prostate-specific membrane antigen positron-emission tomography to guide prostate biopsies and stage men at high-risk of prostate cancer.
  6. Biparametric Magnetic Resonance Imaging-Derived Nomogram to Detect Clinically Significant Prostate Cancer by Targeted Biopsy for Index Lesion.
  7. Local anaesthetic transperineal (LATP) prostate biopsy using a probe-mounted transperineal access system: a multicentre prospective outcome analysis.
  8. Incidence of significant prostate cancer after negative MRI and systematic biopsy in the FUTURE trial.
  9. Patient-reported functional outcomes and oncological control after primary focal cryotherapy for clinically significant prostate cancer: A Phase II mandatory biopsy-monitored study.
  10. Combination of biparametric magnetic resonance imaging with prostate-specific antigen density to stratify the risk of significant prostate cancer: Initial biopsy and long-term follow-up results.